| Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures.Hepatol Int | PMID 36258065PMC9895009 | 2023-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Baseline retinal nerve fiber layer thickness as a predictor of multiple sclerosis progression: New insights from the FREEDOMS II study.Eur J Neurol | PMID 36286605无 PMCID | 2023-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292).Ann Surg Oncol | PMID 36305992PMC9807536 | 2023-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.Arthritis Rheumatol | PMID 36369793PMC10098934 | 2023-Feb | 0.85 | The record describes a randomized, placebo-controlled Phase III extension trial of anifrolumab in systemic lupus erythematosus (SLE), which is a non-oncologic autoimmune disease. The primary endpoints reported are safety and tolerability (serious adverse events, infections, malignancies) and disease activity (SLEDAI-2K). No primary or key secondary time-to-event efficacy endpoints (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or hazard ratio analyses are reported or mentioned. | 待处理 |
| Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.Transplant Cell Ther | PMID 36372355无 PMCID | 2023-Feb | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.Eur Urol Oncol | PMID 36435738无 PMCID | 2023-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study.Breast Cancer Res Treat | PMID 36463547PMC9883304 | 2023-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.Lancet Gastroenterol Hepatol | PMID 36470291无 PMCID | 2023-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Adaptive phase 2/3 designs for oncology drug development - Time to hedge.Contemp Clin Trials | PMID 36509250无 PMCID | 2023-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: Primary analysis and 180-week follow-up results from the phase 3, multicenter IMMspire study.J Dermatol | PMID 36514850PMC10107196 | 2023-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III results for first-line treatment for metastatic colorectal cancer.Nat Rev Gastroenterol Hepatol | PMID 36526904无 PMCID | 2023-Feb | 0.95 | The record describes a Phase III randomized trial with drug intervention in human oncology, but the provided metadata (title, abstract, MeSH terms, keywords) does not explicitly mention or signal a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, Kaplan-Meier, HR). Therefore, it cannot be confirmed as eligible for the cohort. | 待处理 |
| Comparison of short course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: A multicentre, randomised, non-blinded, phase 3 trial.Eur J Cancer | PMID 36535196无 PMCID | 2023-Feb | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study.Aesthetic Plast Surg | PMID 36536093PMC9944721 | 2023-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin.Cancer Commun (Lond) | PMID 36545810PMC9926955 | 2023-Feb | 0.95 | The study is an eligible randomized Phase III oncology trial with a drug intervention, but the primary efficacy endpoint is complete response (a binary categorical outcome) for chemotherapy-induced nausea and vomiting, not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, TTP, nor is the analysis based on Kaplan-Meier estimates or hazard ratios. Therefore, it does not meet the time-to-event efficacy endpoint criterion for inclusion. | 待处理 |
| Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial.Lancet Glob Health | PMID 36565704无 PMCID | 2023-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials.Radiother Oncol | PMID 36572280无 PMCID | 2023-Feb | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| STAR-TREC: An International Three-arm Multicentre, Partially Randomised Controlled Trial Incorporating an External Pilot.Clin Oncol (R Coll Radiol) | PMID 36577551无 PMCID | 2023-Feb | 0.80 | Record is a protocol abstract for a Phase III randomised trial in oncology with time-to-event secondary endpoints, but it does not present formal trial results. Additionally, the drug intervention criterion cannot be clearly established as the trial compares organ preservation strategies (which may include chemoradiation) versus surgery, and the primary endpoint is not time-to-event. Therefore, it is excluded as a protocol without results. | 待处理 |
| Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial.Headache | PMID 36633219无 PMCID | 2023-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.Lancet Oncol | PMID 36642080PMC10337122 | 2023-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2-3 trial.Lancet Neurol | PMID 36681445PMC11847323 | 2023-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial.Nat Med | PMID 36732627PMC9941045 | 2023-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effect of Yoga and Mediational Influence of Fatigue on Walking, Physical Activity, and Quality of Life Among Cancer Survivors.J Natl Compr Canc Netw | PMID 36791754PMC9990873 | 2023-Feb | 0.90 | The study is a randomized Phase III oncology trial but evaluates quality of life and fatigue-related outcomes, not survival, progression, recurrence, death, or closely related time-to-event efficacy outcomes eligible for Kaplan-Meier digitization. | 待处理 |
| [GEM plus CDDP Combination Therapy for Unresectable Biliary Tract Cancer-A Single Institution Experience].Gan To Kagaku Ryoho | PMID 36807184无 PMCID | 2023-Feb | 0.90 | The publication is a primary result report of a human, randomized, Phase III oncology trial with a drug intervention. However, it does not include a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) as required by the cohort definition. The primary efficacy measure reported is disease control rate, which is a categorical, non-time-to-event outcome. | 待处理 |
| Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis.RMD Open | PMID 36828643PMC9972414 | 2023-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Heartburn relief with bicarbonate-rich mineral water: results of the randomised, placebo-controlled phase-III trial STOMACH STILL.BMJ Open Gastroenterol | PMID 36849190PMC9972411 | 2023-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting.BMC Cancer | PMID 36721174PMC9890819 | 2023-Jan-31 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial.Signal Transduct Target Ther | PMID 36717539PMC9885411 | 2023-Jan-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression.J Clin Psychiatry | PMID 36724109无 PMCID | 2023-Jan-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.Lancet | PMID 36709073无 PMCID | 2023-Jan-28 | 0.95 | The study is an oncology, human, randomized, phase 3 trial with a drug intervention (momelotinib) and presents original results. However, the primary endpoint is a symptom response rate (MFSAF TSS response rate), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). | 待处理 |
| Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis.Heart | PMID 36316102PMC9887401 | 2023-Jan-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12-14-month-old children.Vaccine | PMID 36621408无 PMCID | 2023-Jan-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).Vaccine | PMID 36621410无 PMCID | 2023-Jan-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.N Engl J Med | PMID 36511784无 PMCID | 2023-Jan-26 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study.Br J Dermatol | PMID 36689495无 PMCID | 2023-Jan-23 | 0.95 | The study is a Phase III randomized trial with results, but the primary efficacy endpoint is a proportion (binary) at a fixed time point (45 days), not a time-to-event outcome. Furthermore, the intervention (Oleogel-S10, birch triterpenes topical gel) is a non-drug/biological therapy, not a systemic pharmacological agent, which violates the drug-intervention criterion. Therefore, it does not meet the eligibility criteria for inclusion in the oncology Kaplan-Meier digitization cohort. | 待处理 |
| Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.Br J Dermatol | PMID 36689515无 PMCID | 2023-Jan-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.Lancet | PMID 36681415无 PMCID | 2023-Jan-21 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.J Clin Oncol | PMID 35998300PMC9870217 | 2023-Jan-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.J Clin Oncol | PMID 36082969PMC9870219 | 2023-Jan-20 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).J Clin Oncol | PMID 36162037PMC9870220 | 2023-Jan-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).J Clin Oncol | PMID 36206498PMC9870236 | 2023-Jan-20 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression.J Clin Oncol | PMID 36240478PMC9870218 | 2023-Jan-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.J Clin Oncol | PMID 36469833无 PMCID | 2023-Jan-20 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.N Engl J Med | PMID 36652353PMC9933930 | 2023-Jan-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.Clin Cancer Res | PMID 36346687PMC9873250 | 2023-Jan-17 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology.Proc Natl Acad Sci U S A | PMID 36634146PMC9934167 | 2023-Jan-17 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.Lancet | PMID 36495879无 PMCID | 2023-Jan-14 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.Blood | PMID 35714312PMC10644040 | 2023-Jan-12 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis.Blood | PMID 35981565无 PMCID | 2023-Jan-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).Breast Cancer Res | PMID 36631725PMC9832665 | 2023-Jan-11 | 0.85 | The study is a Phase III randomized trial with drug interventions and original results, but its primary efficacy endpoint is pathologic complete response (pCR), which is not a time-to-event outcome. No time-to-event endpoints (OS, PFS, etc.) or associated analyses (Kaplan-Meier, HR) are indicated in the abstract. | 待处理 |
| Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial.J Clin Oncol | PMID 36084276PMC9839269 | 2023-Jan-10 | 0.90 | The record describes a Phase III randomized trial in oncology with a time-to-event primary endpoint (OS). However, the intervention compares a drug-containing regimen (BuCy) to a regimen that includes total body irradiation (TBI-Cy), which is not a drug-containing intervention in both arms. The requirement specifies 'a drug-containing intervention' for both arms in the comparison. Therefore, it is excluded due to insufficient drug intervention evidence for the primary comparison. | 待处理 |